SOPHiA GENETICS (SOPH) EBITDA (2020 - 2025)
Historic EBITDA for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to -$17.9 million.
- SOPHiA GENETICS's EBITDA fell 1626.64% to -$17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.4 million, marking a year-over-year decrease of 27.75%. This contributed to the annual value of -$40.2 million for FY2024, which is 1945.55% up from last year.
- Latest data reveals that SOPHiA GENETICS reported EBITDA of -$17.9 million as of Q3 2025, which was down 1626.64% from -$18.5 million recorded in Q2 2025.
- In the past 5 years, SOPHiA GENETICS's EBITDA ranged from a high of -$9.1 million in Q4 2024 and a low of -$25.0 million during Q1 2022
- Moreover, its 5-year median value for EBITDA was -$17.9 million (2025), whereas its average is -$17.8 million.
- Data for SOPHiA GENETICS's EBITDA shows a peak YoY increase of 9977.38% (in 2021) and a maximum YoY decrease of 21728946.03% (in 2021) over the last 5 years.
- SOPHiA GENETICS's EBITDA (Quarter) stood at -$21.0 million in 2021, then rose by 28.21% to -$15.1 million in 2022, then increased by 19.47% to -$12.1 million in 2023, then rose by 25.49% to -$9.1 million in 2024, then plummeted by 97.35% to -$17.9 million in 2025.
- Its EBITDA stands at -$17.9 million for Q3 2025, versus -$18.5 million for Q2 2025 and -$16.0 million for Q1 2025.